Purinergic receptor transactivation by the β2-adrenergic receptor increases intracellular Ca²⁺ in non-excitatory cells.


Department of Biochemistry, Université de Montréal, Montréal, QC, Canada (WS, ETvdW, A-MS, BP, MB). Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada (WS, ETvdW, A-MS, BP, MH, VL, CLG, MB). Monash Institute for Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (ETvdW). Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (AI, SI, JA). Japan Science and Technology Agency (JST), Precursory Research for Embryonic Science and Technology (PRESTO), Kawaguchi, Saitama, Japan (AI). Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology (AMED-CREST), Chiyoda-ku, Tokyo, Japan (JA).
Running title page:

a) Running title: β2AR transactivation of purinergic receptors

b) Corresponding author: Michel Bouvier, IRIC - Université de Montréal, P.O. Box 6128 Succursale Centre-Ville, Montréal, Qc. Canada, H3C 3J7. Tel: +1-514-343-6319. Fax: +1-514-343-6843. Email: michel.bouvier@umontreal.ca

c) Number of: text pages: 37

            tables: 0

            figures: 8

            references: 58

Number of words in: abstract: 238

            introduction: 572 (max 750)

            discussion: 1029 (max 1500)

d) Non standard abbreviations: 2-APB, 2-aminoethoxydiphenyl borate; AC, adenylyl cylase; β2AR, β2 adrenergic receptor; BAPTA-AM, 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester); BRET, bioluminescent resonance energy transfer; Cch, Carbamylcholine chloride; CTX, cholera toxin; EGFR, epidermal growth factor receptor; FRET, fluorescent resonance energy transfer; HB-EGF, heparin-binding epidermal growth factor; HEK293, human embryonic kidney 293cells; TG, thapsigargin;
**Abstract:**

The $\beta_2$ adrenergic receptor ($\beta_2$AR) increases intracellular $\text{Ca}^{2+}$ in a variety of cell types. By combining pharmacological and genetic manipulations, we reveal a novel mechanism through which the $\beta_2$AR promotes $\text{Ca}^{2+}$ mobilization ($\text{pEC}_{50} = 7.32 \pm 0.10$) in non-excitatory human embryonic kidney (HEK)-293S cells. Down-regulation of Gs with sustained cholera toxin pre-treatment and the use of Gs-null HEK293 ($\Delta$Gs-HEK293) cells generated using the CRISPR/Cas9 system, combined with pharmacological modulation of cAMP formation revealed a Gs-dependent but cAMP-independent increase in intracellular $\text{Ca}^{2+}$ following $\beta_2$AR stimulation. The increase in cytoplasmic $\text{Ca}^{2+}$ was inhibited by P2Y purinergic receptor antagonists as well as a dominant negative mutant form of Gq, a Gq-selective inhibitor and an IP$_3$ receptor antagonist, suggesting a role for this Gq-coupled receptor family downstream of the $\beta_2$AR activation. Consistent with this mechanism, $\beta_2$AR stimulation promoted the extracellular release of adenosine triphosphate (ATP) and pre-treatment with apyrase inhibited the $\beta_2$AR-promoted $\text{Ca}^{2+}$ mobilization. Together, these data support a model whereby the $\beta_2$AR stimulates a Gs-dependent release of ATP, which transactivates Gq-coupled P2Y receptors through an “inside-out” mechanism, leading to a Gq- and IP$_3$-dependent $\text{Ca}^{2+}$ mobilization from intracellular stores. Given that $\beta_2$AR and P2Y receptors are co-expressed in various tissues, this novel signalling paradigm could be physiologically important and have therapeutic implications. In addition, this study reports the generation and validation of HEK293 cells deleted of Gs using the CRISPR/Cas9 genome editing technology that will undoubtedly be powerful tools to study Gs-dependent signalling.
Introduction:

The β2 adrenergic receptor (β2AR) has been shown to regulate a vast signalling network, leading to the activation of key cellular effectors such as adenylyl cyclase (AC), ERK1/2 and Akt (De Blasi, 1990; Daaka et al., 1998; Bommakanti et al., 2000) to control a variety of physiological processes, including the regulation of cardiac function, smooth muscle tone, immunological responses, fat metabolism as well as both central and peripheral nervous system activity (Guimaraes and Moura, 2001; Collins et al., 2004; Sitkauskiene and Sakalauska, 2005; Pérez-Schindler et al., 2013). Although much is known about the signalling repertoire of the β2AR, new insights into its full signalling capabilities and its role in cellular biology continue to be discovered (Stallaert et al., 2012; van der Westhuizen et al., 2014).

In addition to the abovementioned signalling pathways, the β2AR can also stimulate an increase in intracellular Ca\textsuperscript{2+}. This signalling response is well established in excitable cells, such as cardiomyocytes, via a mechanism involving cAMP-mediated regulation of plasma membrane L-type Ca\textsuperscript{2+} channels (Zhang et al., 2001; Christ et al., 2009; Benitah et al., 2010). However, increases in intracellular Ca\textsuperscript{2+} levels have also been observed in non-excitable cells, such as alveolar epithelial cells (Keller et al., 2014) and in human embryonic kidney cells (HEK293) endogenously or stably overexpressing the β2AR (Schmidt et al., 2001; Stallaert et al., 2012; van der Westhuizen et al., 2014). Previous observations from our laboratory indicated that such β2AR-mediated increases in intracellular Ca\textsuperscript{2+} in HEK293 cells are inhibited by an IP\textsubscript{3} receptor antagonist, 2-aminoethoxydiphenyl borate (2-APB) (Stallaert et al., 2012), suggesting the release of Ca\textsuperscript{2+} from intracellular stores, which points to a mechanism distinct from the plasma membrane Ca\textsuperscript{2+} channel activation described in excitable cells.
Several studies have reported that activation of the β2AR can also stimulate the release of extracellular mediators as part of its signalling repertoire. Activation of the β2AR in mouse skeletal muscle, vascular smooth muscle cells or cardiac fibroblasts promotes the extracellular release of cAMP, which is converted to AMP by ecto-phosphodiesterases and then to adenosine by ecto-5’-nucleotidase on the extracellular surface of the cells (Dubey et al., 1996; 2001; Duarte et al., 2012). In addition, extracellular adenosine can be produced by the release of intracellular adenine nucleotides to the extracellular space, which are converted to adenosine by ecto-ATPase, ecto-ADPase and ecto-5’-nuclotidase (Jackson et al., 1996). Stimulation of human erythrocytes with isoproterenol (ISO) increases extracellular ATP levels (Montalbetti et al., 2011), suggesting that βARs can also be coupled to ATP release. In some cases, this release of mediators into the extracellular milieu can lead to the subsequent transactivation of other GPCRs or receptor tyrosine kinases. Previously, an “inside-out” signalling mechanism was demonstrated for the β2AR, leading to the transactivation of adenosine receptors through the production of extracellular adenosine as described above (Sumi et al., 2010), as well as the epithelial growth receptor (EGFR) through the membrane shedding of heparin-binding epithelial growth factor (HB-EGF) (Kim et al., 2002).

In this study, we describe a new “inside-out” pathway activated by the β2AR in non-excitable cells, involving the Gs-dependent, but cAMP-independent increase in intracellular Ca^{2+} through the release of extracellular ATP and the subsequent transactivation of Gq-coupled P2Y purinergic receptors, providing a previously unrecognised link between adrenergic and purinergic receptors. This study also provides the first description and use of CRISPR/Cas9 genomic editing to knockout Gs in human cells, providing a powerful new tool to explore the signalling events downstream of this Gα subunit.
Materials and Methods:

**Reagents:** (-)-isoproterenol hydrochloride (ISO), carbamoylcholine chloride (Cch), thapsigargin (TG), 8-bromo-cAMP (8-br-cAMP), forskolin, cholera toxin (CTX), suramin and apyrase were purchased from Sigma Aldrich (St. Louis, MO, USA). ICI118,551, 1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM), 2-aminoethoxydiphenyl borate (2-APB), 9-(Tetrahydro-2-furanyl)-9H-purin-6-amine (SQ22536), 8,8’-[Carbonylbis(imino-3,1-phenylene)carbonylimino]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt (NF157), 4,4’-(Carbonylbis(imino-3,1-(4-methyl-phenylene)carbonylimino))bis(naphthalene-2,6-disulfonic acid) tetrasodium salt (NF340), 8,8’-[Carbonylbis(imino-4,1-phenylene)carbonylimino-4,1-phenylene)carbonylimino])bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt (NF279), N-Cyano-N’-[(1S)-1-phenylethyl]-N’-5-quinolinyl-guanidine (A-804598), 5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD), 9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine (CGS 15943) and 4,4’,4”,4”’-[Carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid octasodium salt (NF449) were obtained from R&D Systems (Minneapolis, MN, USA). Coelenterazine 400a and coelenterazine h were purchased from Nanolight technologies (Pinetop, AZ, USA) and coelenterazine cp was purchased from Biotium (Hayward, CA, USA). Arginine-vasopressine (AVP) and 5-(Methylamino)-2-[[2R,3R,6S,8S,9R,11R]-3,9,11-trimethyl-8-[(1S)-1-methyl-2-oxo-2-(1H-pyrrol-2-yl)-ethyl]-1,7-dioxaspiro[5.5]undec-2-yl]methyl]-4-benzoxazolecarboxylic acid (A23187) were from Tocris (Bio-Techne, Minneapolis, MN, USA). Cell culture reagents were from Wisent Incorporated (Montreal, QC, Canada). The Gq selective inhibitor, FR900359 (Schrage et al., 2015) was obtained from Dr. Eve Kostenis and Dr. Stefan Kehraus from the
University of Bonn. The Gq and Gq(Q209L/D277N) constructs were purchased from Missouri S&T cDNA Resource Center (Rolla, MO, USA). Hap II, Pvu II and Hae II restriction enzymes were from Takara Bio (Japan). All other reagents were obtained from Sigma-Aldrich unless otherwise stated.

**Cell culture and transfections:** Parental HEK293S cells or HEK293S cells stably expressing an amino-terminal tagged human β2AR (3.17 ± 0.32 pmol/mg protein; HA-β2AR-HEK293S cells; Galandrin et al. 2006) were grown at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum. HEK293S and HA-β2AR-HEK293S cells were transiently transfected (600 000 cells/well) in 6 well plates with biosensors (950 ng/1×10^6 cells) for Ca2+ measurements (Obelin luminescence), bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET) assays using linear polyethylenimine (PEI; 1 mg/ml; Polysciences Inc., Warrington, PA) diluted in NaCl (150 mM, pH 7.0) (PEI:DNA ratio 3:1) as previously described (Reed et al., 2006). Twenty four hours post-transfection, cells were re-plated (50,000 cells/well) onto white 96-well CulturePlates (Perkin-Elmer, Woodbridge, ON, Canada). Six hours after re-plating, growth medium was replaced with fresh starvation media consisting of DMEM supplemented with 0.5% FBS for the next 18 h.

Parental HEK293 and ΔGs-HEK293 cells were cultured and transfected as described for the HEK293S cells, with the following modification: medium was supplemented with 10% FBS, PEI was diluted in Dulbecco's Phosphate-Buffered Saline (DPBS) and added to cells in suspension (300,000-350,000 cells/ml). Cells were then transferred into white 96-well CulturePlates (30,000-35,000 cells/well). Cells were cultured with 10% FBS for the following 48 hrs prior to experimentation.
Generation of HEK293 cells devoided of Gs (ΔGs-HEK293): The two members (Gs and Go, encoded by the GNAS and the GNAL genes, respectively; both were expressed in HEK293 cells) of the Gα family were simultaneously targeted by a CRISPR/Cas9 system to introduce frame shift into the coding sequence as described previously (Ran, et al., 2013) with some modifications. Briefly, GNAS-targeting sgRNA sequence (5’-CTACAACATGGTCATCCGGG-3’) was inserted into the Bbs I site of the pSpCas9(BB)-2A-GFP vector (PX458; a gift from Feng Zhang, Broad Institute; Addgene plasmid # 48138) using two synthesized oligonucleotides (5’-CACCGCTACAACATGGTCATCCGGG-3’ and 5’-AAACCCCGGATGACCACATGTTGTAGC-3’; FASMAC, Japan). Similarly, GNAL-targeting sgRNA sequence #1 (5’-TGTTTGATGTTGGTGGCCAG-3’), #2 (5’-GTAATGTTTGCCGTCACCGG-3’) and #3 (5’-ATTGTGCACAGTCAATCAGC-3’) were inserted using three sets of oligonucleotides (for #1, 5’-CACCGTGTTTGATGTTGGTGGCCAG-3’ and 5’-AAACCTGGCCACCAACATCAACAC-3’; for #2, 5’-CACCGTAATGTTTGCCGTCACCAGG-3’ and 5’-AAACCGGTGACCGCAAACATTAC-3’; for #3, 5’-CACCGATTGTCACACGTCAATCAGC-3’ and 5’-AAACGCTGATTGACTGTGCACAATC-3’). Correct insertion of the sgRNA sequences was verified by sequencing using the Sanger method (FASMAC, Japan). HEK293 (200,000 cells/well) were seeded into 12 well plates and transfected with a mixture of the GNAS-targeting PX458 vectors and either of the GNAL-targeting PX458 vectors (0.25 µg each/well) with Lipofectamine® 2000 (Life Technologies, CA, USA). Twenty four hours later, cells were detached and GFP-positive cells (approximately 30% of cells) were isolated using a cell sorter (SH800, Sony, Japan). After growing clonal cell colonies, clones were analyzed for mutations in the GNAS and the GNAL genes by PCR and
restriction enzyme digestion, using the primer and restriction enzyme combinations shown in
Supplemental Table 1. PCR was performed with an initial denaturation cycle of 95°C for 2 min,
followed by 35 cycles of 95°C for 15 sec, 64°C for 30 sec and 72°C for 30 sec. The resulting
PCR product was digested with the corresponding restriction enzyme and analyzed by agarose
gel electrophoresis. Candidate positive clones were further analyzed by genomic DNA
sequencing using a TA cloning method. The lack of functional Gs was also confirmed by
assessing GPCR-stimulated cAMP production as described below. For the TA cloning, PCR-
amplified genomic DNA fragments using an ExTaq polymerase (Takara Bio, Japan) were gel-
purified (Promega, WI, USA) and cloned into a pMD20 T-vector (Takara Bio, Japan). Ligated
products were introduced into SCS1 competent cells (Stratagene, CA, USA) and transformed
cells were selected on an ampicillin-containing LB plate. At least twelve colonies were picked
and inserted fragments were PCR-amplified using the ExTaq polymerase and primers (5’-
CAGGAAACAGCTATGAC-3’ (M13 Primer RV) and 5’-GTTTTCCCAGTCACGAC-3’ (M13
Primer M4)) designed to anneal the pME20 T-vectors. PCR products of the transformed pMD20
T-vector were sequenced using the Sanger method (FASMAC, Japan) and the M13 Primer RV.

Whole transcriptome expression profiling was performed using the Clariom S assay (human,
analysis using the Transcriptome Analysis Console from Affymetrix) to assess differences in
gene expression between the parental HEK293 and ΔGs-HEK293 cell lines (Supplemental
Figure 5 and Supplemental Tables 2 and 3).

mRNA expression: Total RNA was isolated from 3x10^6 HA-β2AR-HEK293S cells using the
RNAeasy Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol for
animal cells. Microarray analysis of mRNA samples was performed using Illumina’s HumanRef-
8 v3.0 expression bead chips at McGill University and the Génome Québec Innovation Centre.
The gene expression microarray data was analyzed and normalized by the bioinformatics platform at the Institute for Research in Immunology and Cancer (IRIC) at the University of Montreal. The raw fluorescent values were then normalized using a quantile normalization method (Bolstad et al., 2003; Lemieux, 2006), which re-ranks the sampled based on the raw fluorescent values obtained for each probe. Using this method of normalization, the distribution of the samples becomes the reference point, therefore, no internal control is required. For the microarray dataset analyzed, the distribution of the data is defined by the median value 7.162; the minimum value 5.851 and the maximum value 15.760, the first quartile of 6.578 and the third quartile of 9.215. The normalized values were plotted alongside known housekeeping genes, β-actin and α-tubulin, which were used for comparison purposes to represent genes that are highly expressed in the cells. The inhibitory G protein, Go, was also plotted because it is not expressed in HEK293 cells (Law et al., 1993) and therefore represents an appropriate baseline background value.

**Western blot analysis:** The parental HEK293 cells and the ΔGs-HEK293 cells were harvested and approximately 1 x 10^6 cells were lysed in 500 µL of SDS-PAGE sample buffer (62.5 mM Tris-HCl (pH 6.8), 50 mM dithiothreitol, 2% SDS, 10% Glycerol and 4 M urea) containing 1 mM EDTA and 1 mM phenylmethylsulfonyl fluoride. Cell lysates were homogenized with a handy ultrasonic homogenizer (Microtech) and boiled at 95°C for 5 min. Western blots were performed according to standard procedures using an anti-G α s/olf mouse monoclonal antibody (clone E-7, cat. no. sc55546, Santa Cruz Biotechnology) or anti-α-tubulin mouse monoclonal antibody (clone DM1A, cat. no. sc-32293, Santa Cruz Biotechnology) (both at 1 µg/mL in Tris-buffered saline, 1% BSA and 0.05% Tween 20), followed by horse radish peroxidase-linked antimouse IgG secondary antibody (cat. no. NA9310, GE Healthcare; 1:2000 diluted with Tris-
buffered saline, 5% skim milk, 0.05% Tween 20). Chemiluminescence signals were detected using a LAS-4000 (FujiFilm) and visualized with Multi Gauge ver. 3.0 (FujiFilm).

Ca\textsuperscript{2+} measurements: Ca\textsuperscript{2+} measurements were carried out as described previously (van der Westhuizen et al., 2014). Briefly, HEK293S, HA-β\textsubscript{2}AR-HEK293S or ΔGs-HEK293 cells were transiently transfected with the mCherry-obelin or GFP2-obelin-based Ca\textsuperscript{2+}-sensitive biosensors. The day of experimentation, cells were washed twice and pre-incubated in stimulation buffer (Modified Hank’s Balances Salt Solution (HBSS): 137 mM NaCl, 5.4 mM KCl, 0.25 mM Na\textsubscript{2}HPO\textsubscript{4}, 0.44 mM KH\textsubscript{2}PO\textsubscript{4}, 1.8 mM CaCl\textsubscript{2}, 0.8 mM MgSO\textsubscript{4}, 4.2 mM NaHCO\textsubscript{3}, 0.2% (w/v) D-glucose, pH 7.4) containing the obelin substrate, coelenterazine cp (1 μM), at 25°C for 2 h in the dark. Compounds diluted in stimulation buffer were injected into the wells and luminescence readings were taken every 0.3 seconds using the SpectraMax L (Molecular Devices, Sunnyvale, CA). Luminescence was monitored for a total of 60 seconds post-stimulation and expressed as relative luminescence units (RLU). The area under the resulting curves (AUC) and the peak response to stimulation were calculated. Where indicated, the AUC was transformed as % peak ISO or A23187 response.

cAMP production: cAMP production measurements were carried out as described previously (van der Westhuizen et al., 2014). Briefly, cells were transfected as indicated with either the FRET-based GFP\textsubscript{10}-EPAC1-vYFP or the BRET-based GFP\textsubscript{10}-EPAC1-RlucII cAMP-sensitive biosensors in which binding of cAMP induces a conformational change that leads to a decrease in FRET or BRET. Compounds were diluted in stimulation buffer and added to cells at 37°C for 30 minutes prior to measurement. The light emitted from FRET donor and acceptor proteins was measured with the FlexStation II (Molecular Devices, Sunnyvale, CA, USA) using the 510 nm (GFP\textsubscript{10}) and 533 nm (vYFP) emission filters. BRET was measured with the Mithras LB 940...
(Berthold Technologies, Bad Wildbad, Germany) using 410±70 nm (RlucII) and 515±20 nm (GFP<sub>10</sub>) emission filters or the SynergyNeo microplate reader from BioTek using 410±80 nm and 515±30 nm emission filters. FRET or BRET ratios were calculated (acceptor/donor) and ΔFRET and ΔBRET were determined by subtracting the FRET or BRET signal generated in vehicle treatment control conditions.

Measurements of cAMP for Figure 4A were performed using the HTRF-cAMP dynamic kit (Cisbio) as described previously (Stallaert et al., 2012).

**Gs activation assay:** HA-β2AR-HEK293S cells were co-transfected with a three-component G protein activation biosensor composed of Gαs-67-RlucII (50 ng/well), Gβ1 (100 ng/well) and GFP<sub>10</sub>-Gγ1 (100 ng/well) in which Gs activation results in the separation between the Gα and Gβγ subunits, thus leading to a decrease in BRET (Gales et al., 2005). The day of the experiment, cells were washed twice with stimulation buffer and pre-treated with various inhibitors diluted in stimulation buffer for the indicated times at 37°C. Coelenterazine 400a, diluted in stimulation buffer (5 µM) was added to the wells for 5 min, then increasing concentrations of ISO were added for 2 min. Plates were read on the Mithras LB 940 with 410±70 nm (RlucII) and 515±20 nm (GFP<sub>10</sub>) emission filters and BRET ratios calculated as above.

**Quantification of extracellular ATP:** Extracellular ATP was measured using the luciferin-luciferase-based ENLITEN® ATP Assay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, cells were grown to 90-100% confluence in a 96-well plate. Cells were washed with stimulation buffer, then pre-treated with 10 µM ICI 118,551 or stimulation buffer (vehicle) for 30 min at 37°C. Cells were stimulated with 10 µM ISO and the cell supernatant (conditioned buffer) was collected at 15-120 sec post stimulation. Luciferin-
luciferase reagent (100 µl) was injected into 10 µl of conditioned buffer, and luminescence was measured on the Mithras LB 940 (Berthold Technologies, Bad Wildbad, Germany). ATP concentration of each sample was determined by comparing the luminescence of samples with those of standards in the concentration range of 10^{-6} to 10^{-10} M.

**Data Analysis:** Data analysis was performed using Microsoft Excel (Microsoft, Redmond, WA, USA) and GraphPad Prism (versions 5 and 6, GraphPad Software, La Jolla, CA, USA). Statistical analyses were performed as indicated in Figure legends.
Results:

\( \beta_2 \text{AR activation leads to an increase in intracellular } Ca^{2+} \text{ in HEK293S cells:} \) Isoproterenol (ISO) stimulation of the endogenously expressed \( \beta_2 \) ARs in HEK293S cells induces a rapid and transient increase in intracellular \( Ca^{2+} \) (Figure 1A). The increase in intracellular \( Ca^{2+} \) was detected as early as 5 seconds following the addition of ISO, reaching a maximum at approximately 12 seconds followed by a slow decrease thereafter and returning to basal levels 60 seconds post-stimulation, demonstrating a functional \( Ca^{2+} \) response in non-excitable cells that endogenously express the receptor. Stable overexpression of the \( \beta_2 \) AR in HEK293S cells (HA-\( \beta_2 \) AR-HEK293S cells) led to acceleration in the onset (\( \approx 2 \) sec) and increased magnitude of the response (Figure 1B). This increase in intracellular \( Ca^{2+} \) was inhibited in both cell lines following pre-treatment with the \( \beta_2 \) AR-selective antagonist, ICI 118,551, confirming the \( \beta_2 \) AR-specificity of the response (Figure 1C). The response was concentration-dependent, yielding similar pEC\(_{50} \) values for ISO in both cell lines (7.32±0.10 and 7.05±0.16 in HEK293S and HA-\( \beta_2 \) AR-HEK293S cells, respectively) (Figure 1D).

\( \beta_2 \text{AR promotes a Gs-dependent but cAMP-independent } Ca^{2+} \text{ response:} \) To probe the mechanism underlying the \( \beta_2 \) AR-mediated \( Ca^{2+} \) response, we first examined the Gs/cAMP pathway in the HA-\( \beta_2 \) AR-HEK293S cell line, which produces a larger \( Ca^{2+} \) response following stimulation, thus facilitating its mechanistic dissection. To confirm the involvement of Gs, the primary G protein-coupling partner of the \( \beta_2 \) AR, we tested the effect of overnight pre-treatment with cholera toxin (CTX) to down-regulate Gs signalling (Levis and Bourne, 1992), as well as the effect of acute pre-treatment with a small molecule inhibitor of Gs, NF449 (which prevents GDP/GTP exchange (Hohenegger et al., 1998)). We found that the ISO-stimulated \( Ca^{2+} \) response was significantly inhibited by both CTX and NF449 pre-treatment (Figure 2A), suggesting the
involvement of Gs in the β2AR-mediated Ca2+ response. However, while chronic pre-treatment with CTX led to the expected inhibition of Gs activation measured using a bioluminescence resonance energy transfer (BRET)-based biosensor that monitors the separation between Gαs and Gγ1 as a reporter for G protein activation (Gales et al., 2005), acute pre-treatment with NF449 had no impact on Gs activation (Figure 2B), indicating that its effect on the β2AR-promoted Ca2+ response resulted from another mechanism of action. This is consistent with the fact that, although a potent and selective inhibitor of Gαs, NF449 contains multiple negative charges (El-Ajouz et al., 2012) that impede its cell permeability and likely restrict its effect to extracellular target(s) in cell-based assays. Observations that NF449 is also a potent antagonist of purinergic P2X and P2Y receptors (Braun et al., 2001; Kassack et al., 2004) provided valuable insights into additional mechanistic components underlying the β2AR-stimulated Ca2+ response, as discussed below. However, the inhibitory effect of sustained CTX treatment supported a role for Gs in the Ca2+ response.

To confirm the role of Gs in the cytoplasmic Ca2+ increase, we genetically deleted functional Gs from HEK293 cells using the CRISPR/Cas9 system (ΔGs-HEK293). The genetic characterization of three ΔGs cell clones is presented in Supplemental Figures 1-4. Loss of both the long (GαsL) and the short (GαsS) forms of Gαs was confirmed in 3 ΔGs-HEK293 clones (Figure 2C).

ΔGs cells were then tested for a loss of function using the BRET-based EPAC biosensor to monitor the effect of Gs knockout on the β2AR-mediated cAMP response. In ΔGs-HEK293 cells, the cAMP response to ISO stimulation was significantly reduced compared to parental HEK293 cells (Figure 2D, Supplemental Figure 4A). Similarly, stimulation of another Gs-coupled receptor, the vasopressin type 2 receptor, with AVP failed to promote cAMP accumulation in all
3 ΔGs-HEK293 selected clones (Supplemental Figure 4B). Furthermore, the ISO-promoted increase in intracellular Ca\(^{2+}\) was also found to be inhibited in ΔGs-HEK293 cells (Figure 2E, Supplemental Figure 4C), while the response to the Ca\(^{2+}\) ionophore, A23187, was similar to that observed in parental HEK293 cells (Figure 2F, Supplemental Figure 4C), thus confirming the essential role of Gs in the β\(_2\)AR-promoted Ca\(^{2+}\) response. The loss of Ca\(^{2+}\) responses to β\(_2\)AR stimulation was observed in all 3 ΔGs-HEK293 clones (Supplemental Figure 4C), excluding a possible clonal effect. Furthermore, a gene array analysis (Supplemental Figure 5) of the parental and one of the ΔGs-HEK293 cells (clone 1) revealed that none of the other G protein subunit (α, β or γ) were among the 489 genes (out of 21,448 genes detected) found to be significantly up or down regulated with a minimum threshold of 2 fold in the ΔGs cells (Supplemental Table 2), excluding the possible implication of other G protein expression changes in the observed responses. The expression level of the G protein subunits detected in the microarray for parental and ΔGs cells are presented in Supplemental Table 3.

We next assessed the role of the Gs-, and adenylate cyclase (AC)-dependent second messenger cAMP in the ISO-promoted Ca\(^{2+}\) response. Pre-treatment with SQ22536, a pharmacological inhibitor of AC, significantly inhibited ISO-promoted cAMP production (by 43%; Figure 3A), yet it failed to block the Ca\(^{2+}\) response (Figure 3B), producing a response higher than in the absence of the inhibitor. To further confirm this surprising result, we directly assessed whether increases in intracellular cAMP alone were capable of generating a Ca\(^{2+}\) response. Stimulation with forskolin (Fsk), which increases cAMP independently of β\(_2\)AR activation through the direct activation of AC (Seamon et al., 1981), increased the intracellular cAMP to a similar level as obtained for ISO (Figures 2D and 3C), yet elicited only a marginal Ca\(^{2+}\) response (Figure 3D). Further supporting these results, the cell permeable cAMP analog, 8-
bromo-cAMP, elicited a similarly weak Ca\textsuperscript{2+} response (Figure 3E). Taken together, our data indicate the $\beta_2$AR-promoted increase in intracellular Ca\textsuperscript{2+} occurs predominantly independently of cAMP production.

**Involvement of purinergic receptors in the $\beta_2$AR-promoted Ca\textsuperscript{2+} response:** To further investigate the above observation that NF449, a small molecule inhibitor of Gs and a purinergic receptor antagonist (Braun et al. 2001; Kassack et al. 2004), blocked the ISO-promoted Ca\textsuperscript{2+} response (see Figure 2A), we assessed additional purinergic receptor antagonists to test the potential role of this receptor family. Pre-treatment with a pan-purinergic receptor antagonist, suramin, significantly inhibited the ISO-promoted increase in intracellular Ca\textsuperscript{2+} (Figure 4A), while the pan-adenosine receptor antagonist CGS 15943 had no effect (Figure 4B). Gene expression microarray analysis of HA-\(\beta_2\)AR-HEK293S cells indicated the expression of several P2X purinergic ion channels and P2Y purinergic GPCRs in this cell line (Supplemental Figure 6). To determine the identity of the purinergic receptor(s) involved in the Ca\textsuperscript{2+} response, we selectively inhibited the most highly expressed subtypes. NF279 (P2X1-selective), 5-BDBD (P2X4-selective) and A804598 (P2X7-selective) were without effect, while NF157 (P2Y11/P2X1-selective) and NF340 (P2Y11-selective) significantly inhibited the ISO-promoted Ca\textsuperscript{2+} response (Figure 4C), suggesting a role for the P2Y11 purinergic receptor. The effect of NF449 (Figure 2A), NF340 and NF157 (Figure 4C) was specific to the $\beta_2$AR-stimulated response since these compounds did not significantly inhibit the carbamylcholine chloride (Cch)-stimulated increase in Ca\textsuperscript{2+} via endogenously expressed Gq-coupled muscarinic receptors in HA-\(\beta_2\)AR-HEK293S cells (Figures 4D). The effect of the P2Y11-selective antagonist, NF340, was concentration-dependent and resulted in a decrease in the $E_{\text{max}}$ of the ISO-promoted Ca\textsuperscript{2+} response, with no significant effect on the EC\textsubscript{50} (Figure 4E), confirming that its effect does not
occur directly through a competitive blockade of the β₂AR but instead suggesting a non-competitive antagonism of the response. Furthermore, both NF340 and NF157 were found to progressively decrease the ISO-promoted Ca²⁺ response in a dose-dependent manner, with potencies compatible with their affinity for the purinergic receptors (Figure 4F).

A previous study demonstrated that β₂AR activation could induce the release of adenine nucleotides from HEK293 cells (Sumi et al., 2010). To determine if the β₂AR promotes a Ca²⁺ response through the release of an extracellular mediator, leading to the subsequent transactivation of a purinergic receptor, we performed co-culture experiments in which parental HEK293S cells transfected with the obelin Ca²⁺ biosensor (obelin-HEK293S responder cells) were co-cultured at a 1:1 ratio with either parental HEK293S cells or with HA-β₂AR-HEK293S cells not expressing the biosensor (releaser cells). When obelin-HEK293S responders were co-cultured with releaser cells overexpressing the β₂AR (HA-β₂AR-HEK293S), a significant potentiation in the Ca²⁺ response was observed following ISO treatment compared to co-culture with parental HEK293S releaser cells (Figure 5A), suggesting a role for the β₂AR-dependent release of an extracellular mediator acting in a paracrine manner. As a control experiment, we examined the Ca²⁺ response to Cch stimulation in both co-culture conditions and found no significant difference (Figure 5B), further supporting the β₂AR-specificity of this paracrine signalling response.

Since both ATP and ADP adenine nucleotides act as agonists for the P2Y11 receptor (van der Weyden et al., 2000), we assessed the role of extracellular adenine nucleotides in the β₂AR-promoted Ca²⁺ response, by pre-treating cells with apyrase, a cell-impermeable enzyme that hydrolyses both ATP and ADP to AMP. Apyrase treatment decreased both the efficacy (34% decrease in Eₘₐₓ) and potency (increase in EC₅₀ from 9.2x10⁻⁸ M to 1.7x10⁻⁶ M) of the ISO-
promoted response (Figure 5C), consistent with the depletion of an extracellular mediator released upon β2AR activation and acting in trans on the P2Y11 receptor. The Cch-mediated Ca\(^{2+}\) response, on the other hand, was not inhibited and instead was increased following apyrase treatment (Figure 5D). Consistent with adenine nucleotides being the paracrine mediator responsible for the transactivation, ISO treatment promoted the release of ATP from HA-β2AR-HEK293S cells (Figure 6A), with kinetics similar to those of the ISO-promoted Ca\(^{2+}\) response (reaching a maximum at 15 sec and returning to basal levels by 60 seconds). This ATP release was blocked by the β2AR-selective antagonist, ICI 118,551, supporting a role for β2AR in the response (Figure 6B). These results are consistent with the hypothesis that β2AR activation leads to the release of adenine nucleotides, which can act in trans on P2Y11 receptors to activate a Ca\(^{2+}\) response.

**P2Y11 transactivation elicits a Gq-dependent increase in Ca\(^{2+}\) from intracellular stores:** To investigate the potential role of Gq activation following P2Y11 transactivation (Qi et al., 2001), we tested the effects of overexpressing either WT G\(\alpha\)q or a dominant-negative mutant form of Gq (Gq-Q209L/D277N). Overexpression of WT Gq in HA-β2AR-HEK293S cells increased the magnitude of the ISO-promoted Ca\(^{2+}\) response, whereas overexpression of Gq-Q209L/D277N or pre-treatment with the Gq-selective inhibitor FR900359 (Schrage et al., 2015) completely abolished the response (Figure 7). These results further support the involvement of a Gq-coupled receptor downstream of the β2AR in the Ca\(^{2+}\) response.

We next assessed whether the increase in intracellular Ca\(^{2+}\) occurs via release from intracellular stores, as is typical for Gq-mediated responses. For this purpose, cells were pre-treated with the IP\(_3\) receptor antagonist, 2-APB, the cell-permeable Ca\(^{2+}\) chelator, BAPTA-AM, or the sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase inhibitor, thapsigargin (TG). Upon stimulation
with ISO, the Ca\(^{2+}\) response was completely blocked by all three inhibitors (Figure 8A). These inhibitors had a similar effect on the Cch-mediated Ca\(^{2+}\) response, which activates a well-characterized IP\(_3\)-dependent pathway via activation of Gq-coupled muscarinic receptors (Caulfield, 1993) (Figure 8B). Together these data are consistent with the proposed transactivation of the Gq-coupled P2Y11 receptor upon activation of the \(\beta_2\)AR.
Discussion:

In this study, we describe a new node in the \( \beta_2 \)AR signalling network involving a Gs-dependent but cAMP-independent release of ATP, which transactivates P2Y11 purinergic receptors and subsequently initiates a Gq-dependent mobilization of intracellular Ca\(^{2+} \). This discovery is consistent with the accumulating reports that receptor transactivation, via the production and/or release of an extracellular mediator acting on a distal receptor, represents a bona fide signalling event for many GPCRs (Ostrom et al., 2000; Gschwind et al., 2001; Lee et al., 2002; Sumi et al., 2010). Given that the \( \beta_2 \)AR and the P2Y receptors are co-expressed in various non-excitable tissues, including the brain, gastrointestinal tract, lung, adipocytes, kidney, skeletal muscle, heart and liver (Andre et al., 1996; Nicholas et al., 1996; Moore et al., 2001), the results obtained in the current study could provide additional insight into how \( \beta_2 \)AR and P2Y receptors might collaborate in normal conditions and pathophysiology.

In addition to characterizing a new signalling modality for the \( \beta_2 \)AR, the present study introduces a new genetically engineered HEK293 cell line lacking both members of Gs (Gs and Golf), offering a powerful tool to directly assess the contribution of Gs to cellular event. Current methods to investigate the role of Gs involve either overnight treatment with CTX, which initially causes chronic activation of Gs to stimulate its downregulation, the use of the few currently available small molecule inhibitors, which provide poor target specificity, and/or inhibition of the downstream effectors AC or protein kinase A. Genetic knockout of Gs provides a useful tool to specifically investigate the role of Gs and, as was the case in the present study, allow the discovery of Gs-dependent responses that do not require cAMP production. These cells should prove useful in future studies to explore additional non-canonical Gs signalling pathways.
Although the β2AR-mediated release of adenine nucleotides has been described previously (Baker et al., 2004; Sumi et al., 2010), the functional consequences of this signalling event are just beginning to be explored. P2Y11 mRNA was the most abundant in HEK293S cells and it has the highest affinity for ATP compared to other purinergic receptors expressed in these cells (von Kügelgen et al., 2006). Yet, the capacity of the β2AR to stimulate the release of ATP may in fact lead to the activation of other purinergic receptor subtypes in cells expressing a different repertoire or spatial organization of receptors.

The mechanism described in this study differs from previous reports of β2AR-mediated Ca²⁺ responses in non-excitable HEK293 cells, which suggested a cAMP-dependent increase in intracellular Ca²⁺, through a mechanism involving exchange protein directly activated by cAMP (EPAC) and phospholipase Cε or calcium release activated calcium (CRAC) channels (Schmidt et al., 2001; Keller et al., 2014). Although we cannot exclude a contribution of these mechanisms to the Ca²⁺ response studied here, our data clearly indicate that β2AR activation in HEK293 cells can elicit a Ca²⁺ response independently of cAMP since blocking approximately 50% of the cAMP production did not affect the Ca²⁺ response (Figure 3A,B). Moreover, direct elevation of cAMP following treatment with forskolin or the cAMP analogue 8-Br-cAMP elicited only marginal Ca²⁺ responses compared to β2AR stimulation (Figure 3D,E). Whether CRAC could subsequently contribute to the response following the initial Ca²⁺ mobilisation from the ER pool described in the current study has not been investigated. Interestingly, these previous studies used the Fura-2 indicator dye to measure intracellular Ca²⁺, which is dissolved in the non-ionic detergent pluronic F127. This detergent inhibits the multi-drug resistant proteins (ABC-B transporters), which have been implicated in ATP transport to the extracellular space (Guan et al., 2011). The use of the genetically encoded obelin Ca²⁺ biosensor in the current study should
not interfere with this ATP release mechanism and may have aided in the elucidation of the mechanism described in the current work.

This collaboration between the β₂AR and purinergic receptors may be of particular relevance in the context of the airway epithelium. Indeed, the β₂AR plays an important role in the cAMP-dependent secretion of airway surfactants, ciliary beating and regulation of mucosal clearance (Wright and Dobbs, 1991; Salathe, 2002), properties that contribute to the therapeutic success of β₂AR agonists for the treatment of asthma (Giembycz and Newton, 2006). Interestingly, activation of Gq-coupled receptors and increases in intracellular Ca²⁺ promote undesirable inflammatory responses in pulmonary tissues (Barnes, 1998; Rider et al., 2011). Furthermore, an increase in purine nucleotide release from the airway epithelium is a hallmark of inflammatory diseases in the lungs (Burnstock et al., 2012) and purinergic signalling has been proposed to participate in asthmatic airway inflammation (Basoglu et al., 2005; Idzko et al., 2007) as well as in the pathogenesis of chronic obstructive pulmonary disorder (COPD) (Adriaensen and Timmermans, 2004; Mortaz et al., 2010). Given the beneficial effects of cAMP production and deleterious consequences of increases in intracellular Ca²⁺ in airway epithelia, the identification of functionally selective β₂AR ligands that stimulate cAMP production without promoting Ca²⁺ mobilization could represent a desirable class of β₂AR agonists for the treatment of pulmonary disorders. Salmeterol, a clinically effective β₂AR agonist used in the treatment of asthma, exhibits less side effects than what is typically associated with chronic use of other β₂AR agonists (Cazzola et al., 2013). Biased signalling studies have also shown that salmeterol is highly efficacious towards cAMP production but does not increase intracellular Ca²⁺ (van der Westhuizen et al., 2014). Given the results obtained in the current work, future studies examining the influence of purinergic receptor transactivation in the context of β₂AR-targeted treatment of
pulmonary disorders could be of great interest. Indeed, it is tempting to speculate that optimal therapy for such pulmonary disorders might involve harnessing the therapeutic benefit of β-adrenergic-mediated cAMP/PKA activity while avoiding the pro-inflammatory effect of purinergic transactivation and subsequent Ca^{2+}-dependent signalling.

Our study demonstrates a novel “inside-out” pathway for the β2AR, adding to its signalling repertoire the transactivation of purinergic receptors and stimulation of Ca^{2+} mobilization. Given the preponderance of data supporting such transactivation mechanisms for both the β2AR and other GPCR family members, we propose that such “inside-out” signalling events are not rare occurrences and instead represent a common signalling motif for GPCRs that may provide tissue-specific signalling in cells expressing a given repertoire of receptors.
Acknowledgements:

a) The authors would like to thank Dr. Monique Lagacé for critical reading of the manuscript. We would also like to thank Dr. Kumiko Makide and Yuji Shinjo for technical assistant of flow cytometry cell isolation and Kouki Kawakami for Western blot analysis.
Authorship contributions:

Participated in research design: Stallaert, van der Westhuizen, Le Gouill, Bouvier

Conducted Experiments: Stallaert, van der Westhuizen, Schonegge, Plouffe, Hogue, Lukashova

Contributed to new reagents or analytical tools: Inoue, Ishida, Aoki, Le Gouill

Performed data analysis: Stallaert, van der Westhuizen, Schonegge, Plouffe, Hogue, Lukashova, Inoue, Bouvier

Wrote or contributed to the writing of the manuscript: Stallaert, van der Westhuizen, Inoue, Bouvier
References:


Footnotes:

a) This work was supported, in part, by grants from the Canadian Institutes for Health Research (CIHR) [MOP 11215] to MB, PRESTO, JST to AI and AMED-CREST, AMED to JA. WS was supported by the Vanier Canada Graduate Scholarship from the CIHR. ETvdW was supported by post-doctoral research fellowships from the CIHR, the Canadian Hypertension Society, the Fonds de la Recherche en Santé du Québec (FRSQ) and the National Health and Medical Research Council Australia (NHMRC) [GNT-1013819]. A-MS was supported by post-doctoral research fellowships from the FRSQ while BP was supported by post-doctoral research fellowships from the CIHR. MB holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology.

b)  

c) Reprint requests to: Michel Bouvier, IRIC - Université de Montréal, P.O. Box 6128 Succursale Centre-Ville, Montréal, Qc. Canada, H3C 3J7. Email: michel.bouvier@umontreal.ca

d) WS and ETvdW contributed equally to this work.
Figure legends:

**Figure 1 – Isoproterenol increases intracellular Ca\(^{2+}\) via the β\(_2\)AR.** HEK293S (endogenously expressing β\(_2\)AR at 18.74±3.14 fmol/mg protein) or HA-β\(_2\)AR-HEK293S (stably expressing β\(_2\)AR at 3 174±320 fmol/mg protein) cells were transiently transfected with mCherry-obelin. (A-B) Cells were treated with vehicle or isoproterenol (ISO; 10 μM) and increases in intracellular Ca\(^{2+}\) (increases in obelin relative luminescence unit, RLU) were measured. (C) Cells were pre-treated with vehicle (Ctl) or ICI 118,551 (ICI, 100 nM) for 1 h, then treated with ISO (10 μM). Data represent ISO-promoted peak Ca\(^{2+}\) responses. (D) The Ca\(^{2+}\) response was measured with increasing concentrations of ISO. EC\(_{50}\) values: 7.32±0.10 for HEK293S and 7.05±0.16 for HA-β\(_2\)AR-HEK293S. Data are expressed as the mean ± S.E.M. of 3-4 independent experiments, each performed in triplicate. Data in column graphs were analyzed by two-tailed paired Student’s t-test, where p<0.05 (*) was considered significant.

**Figure 2 – The ISO-promoted increase in intracellular Ca\(^{2+}\) is Gs-dependent.** (A) HA-β\(_2\)AR-HEK293S cells transiently transfected with mCherry-obelin were pre-treated with cholera toxin (CTX) (200 ng/ml; 18 h) or with NF449 (10 µM; 1 h). Cells were treated with isoproterenol (ISO; 10 μM) and increases in intracellular Ca\(^{2+}\) were measured. *Inset:* The area under the curve (AUC) was calculated for each treatment. (B) HA-β\(_2\)AR-HEK293S cells were transiently transfected with G\(_{αs}\)-67-RlucII and GFP\(_{10}\)-G\(_{γ}\)1. Cells were pre-treated with vehicle (Ctl), CTX or NF449, as indicated above, followed by ISO treatment, and Gs activation was measured as a decrease in the BRET response. Protein extracts from parental HEK293 and three clones of ΔG\(_{s}\)-HEK293 cells were separated on SDS-PAGE and immunoblotted with anti-G\(_{αs}\)/olf antibody (top
panel) or anti-α-tubulin antibody (bottom panel). Note that the parental HEK293 cells express
the long (GαsL) and short (GαsS) Gαs isoforms while they were both undetectable in the mutant
clones. (D) The parental HEK293 or ΔGs-HEK293 (Clone1) cells were transiently transfected
with GFP10-EPAC-RlucII. Cells were then treated with either isoproterenol (ISO; 10 μM) or
forskolin (Fsk; 10 μM) for 20 min. ISO increased intracellular cAMP levels in HEK293 cells at a
similar level to Fsk while the response to ISO was significantly blocked in ΔGs-HEK293 cells.
(E-F) The parental HEK293 or ΔGs-HEK293 (Clone1) cells were transiently transfected with
β2AR and Obelin-GFP2, and treated with ISO (10μM, C) or the Ca²⁺ ionophore A23187 (10
μM, D). ISO increased intracellular Ca²⁺ in the parental HEK293 cells while the response was
blocked in ΔGs-HEK293 cells (E). The response to the Ca²⁺ ionophore A23187 was comparable
in both cells lines (F). cAMP and Ca²⁺ data for the 2 other clones are shown in Supplemental
Figure 4. Data are expressed as the mean ± S.E.M. of 3-6 independent experiments, each
performed in duplicate or triplicate. Data in panel A were analyzed by one-way ANOVA, with a
Dunnett’s multiple comparison post-hoc test, where p<0.05 (*) was considered significant. Data
in panel D were analyzed by two-way ANOVA followed by a Sidak’s multiple comparison
post-hoc test, where p<0.05 (*) and p<0.001 (*** )was considered significant.

Figure 3 – The ISO-promoted increase in Ca²⁺ is independent of cAMP production. (A)
HA-β₂-AR-HEK293S cells were pretreated with vehicle or the adenylyl cyclase inhibitor,
SQ22536 (100 mM, 1 h), then treated with isoproterenol (ISO; 10 μM) and cAMP measured
using the Cisbio kit. (B-E) HA-β₂-AR-HEK293S cells were transiently transfected with either
GFP₁₀-EPAC-vYFP (C) or mCherry-obelin (B, D-E). (B) Cells were treated as in A and Ca²⁺
response measured. Inset: Ca²⁺ response was plotted using the area under the curve (AUC).
SQ22536 significantly inhibited ISO-promoted cAMP production, but did not attenuate the ISO-induced Ca\textsuperscript{2+} response. (C-D) Cells were treated with either forskolin (Fsk; 100 μM, 30 min) or ISO and cAMP (C) and Ca\textsuperscript{2+} (D) responses were measured. Fsk activates cAMP production to a similar extent as ISO (C), but stimulates only a marginal Ca\textsuperscript{2+} response compared to ISO (D) and over vehicle (D, inset). (E) Cells were stimulated or not (vehicle) with ISO or the non-hydrolysable cAMP analog, 8-bromo-cAMP (100 μM) and Ca\textsuperscript{2+} response measured. Inset: Ca\textsuperscript{2+} response was plotted using the area under the curve (AUC). Data are expressed as the mean ± S.E.M. of 3-6 independent experiments, each performed in duplicate or triplicate. Column graphs were analyzed by two-tailed paired Student’s t-tests, where p<0.05 (*) was considered significant.

**Figure 4 – The ISO-promoted Ca\textsuperscript{2+} response is inhibited upon purinergic receptor blockade.** (A-E) HA-β2AR-HEK293S cells transiently transfected with mCherry-obelin were pretreated with the pan-adenosine receptor antagonist CGS15943 (1 μM, 30 min) (B) or the purinergic receptor antagonists: suramin (500 μM; 1 h) (A, C), NF279 (1 μM, 30 min) (C), 5-BDBD (10 μM, 30 min) (C), A804598 (1 μM, 30 min) (C), NF449 (10 μM, 30 min) (D), NF157 (10 μM, 30 min) (C-D) or NF340 (10 μM, 30 min) (C-D). Cells were then stimulated with either ISO (10 μM) (A-C, E) or Carbamylcholine chloride (Cch, 100 μM) (D), and the Ca\textsuperscript{2+} response was measured. Inset in A and B shows the Ca\textsuperscript{2+} response plotted using the area under the curve (AUC). (E) Cells were pre-treated with vehicle (Ctl) or the indicated concentration of NF340, followed by stimulation with increasing concentrations of ISO and the Ca\textsuperscript{2+} response was measured. (F) Cells were pretreated with increasing concentration of either NF157 or NF340, followed by stimulation with ISO at an EC\textsubscript{80} concentration (150 nM). Ca\textsuperscript{2+} response was then
measured. IC_{50} values: 4.36 ± 1.91 μM for NF157 and 50.4 ± 27.5 μM for NF340. Data are expressed as the mean ± S.E.M. of 3-4 independent experiments, each performed in triplicate. Area under the curve (AUC) data presented in column graphs were analyzed by two-tailed unpaired Student’s t-tests, where p<0.05 (*) was considered significant.

Figure 5 – ISO stimulates the releases of an extracellular mediator involved in the Ca^{2+} response. Parental HEK293S cells were transiently transfected with mCherry-obelin and co-cultured with HEK293S or HA-β2AR-HEK293S cells not expressing the biosensor. (A-B) Cells were treated with either ISO (10 μM) (A) or Cch (100 μM) (B) and the Ca^{2+} response was measured. (C-D) Cells were pre-treated with apyrase (1 UI/ml; 1 h) followed by stimulation with increasing concentration of ISO (C) or Cch (100 μM) (D) and the Ca^{2+} response was measured. Inset for A, B and D: Ca^{2+} response plotted using the area under the curve (AUC). Data are expressed as the mean ± S.E.M. of 3 independent experiments, each performed in triplicate. Area under the curve (AUC) data presented in column graphs were analyzed by two-tailed paired t-tests, where p<0.05 (*) was considered significant.

Figure 6 – ISO promotes ATP release in HA-β2AR-HEK293S cells. HA-β2AR-HEK293S cells were stimulated with ISO (10 μM) for different time points and ATP was measured in the bulk media. (A) ISO promoted a rapid and transient release of ATP over a period of 60 sec, with peak release measured at 30 sec. (B) The response to ISO was blocked in both HEK293S and HA-β2AR-HEK293S cells pre-treated with the β2AR-selective antagonist ICI 118551. Data are the mean ± S.E.M. of 2-4 independent experiments performed in duplicate.
Figure 7 – The ISO-promoted Ca^{2+} response is modulated by wild-type or dominant negative Gq overexpression. HA-β_{2}AR-HEK293S were transiently transfected or not (Mock) with either wild-type Gq or a dominant negative mutant of Gq (Q209L/D277N) (Gq-DN), or pre-treated with the Gq-selective inhibitor FR900359, and the Ca^{2+} response was measured. Data are expressed as the mean ± S.E.M. of 4-5 independent experiments, each performed in triplicate.

Figure 8 – Ca^{2+} originating from the intracellular stores is involved in the ISO and Cch-mediated responses. HA-β_{2}AR-HEK293S cells were pre-treated with the sarco/endoplasmic reticulum Ca^{2+}-ATPase inhibitor thapsigargin (Tg; 5 μM, 1 h), the cell-permeable Ca^{2+} chelator BAPTA-AM (20 μM, 1 h), or the IP_{3} receptor antagonist 2-aminoethoxydiphenyl borate (2-APB; 200 μM, 1 h), followed by stimulation with ISO (10 μM) (A) or Cch (100 μM) (B) and the Ca^{2+} response was measured. Inset for A and B: Ca^{2+} response plotted using the area under the curve (AUC). Data are expressed as the mean ± S.E.M. of 3-6 independent experiments, each performed in triplicate. Area under the curve (AUC) data in column graphs were analyzed by one-way ANOVA, with a Dunnett’s multiple comparison post-hoc test, where p<0.05 (*) was considered significant.
FIGURE 1

A

HEK293S

Ca²⁺ response (RLU x 10⁵)

Time (sec)

B

HA-β2AR-HEK293S

Ca²⁺ response (RLU x 10⁵)

Time (sec)

C

HEK293S

Ha-β2AR-HEK293S

Ca²⁺ response (peak RLU x 10⁵)

D

HEK293S

Ha-β2AR-HEK293S

Ca²⁺ response (peak RLU x 10⁵)
FIGURE 2

A

B

C

D

E

F

This article has not been copyedited and formatted. The final version may differ from this version.
FIGURE 3

A. CAMP response (pmol/well)

B. Ca²⁺ response (% peak ISO)

C. CAMP response (ΔFRET)

D. Ca²⁺ response (% peak ISO)

E. Ca²⁺ response (% peak ISO)
FIGURE 4

A

B

C

D

E

F

This article has not been copyedited and formatted. The final version may differ from this version.
FIGURE 5

A

ISO

HEK293S

HA-J2AR-HEK293S

B

Cch

HEK293S

HA-J2AR-HEK293S

C

HA-J2AR-HEK293S

ISO

ISO + apyrase

D

HA-J2AR-HEK293S

Cch

Cch + apyrase

This article has not been copyedited and formatted. The final version may differ from this version.
FIGURE 6

A

HA-β2AR-HEK293S

ATP release (nM)

ATP release (% control)

Time (sec)

0 20 40 60

B

ISO + ICI

ISO + ICI

HEK293S

HA-β2AR-HEK293S

ATP release (% control)
FIGURE 7

![Graph showing Ca^2+ response](image-url)
FIGURE 8

A

B